Arecor, backed by Unilever Ventures, aims to pioneer and develop dramatically better delivery forms for proteins & biological therapies.Find out more
By applying science of the highest calibre Arecor uncovers new insights in protein chemistry, enabling development of differentiating next generation biologics.
The Arecor technology has a demonstrated potential to significantly improve the stability of complex biologicals by using novel formulation design principles.
Arecor’s biologic stabilisation technology provided the stabilisation breakthrough needed for commercialisation of Oxyzyme and Iodozyme, Archimed's unique wound healing products.
We are very pleased with the work Arecor has done with our lead vaccine candidate REDEE FLU™. Providing a more effective influenza vaccine that maintains its stability is our ultimate goal at FluGen and we are indebted to the UK government and Arecor for making this possible.
Arecor has transformed the development paths and delivery options for a wide range of new therapeutic products by working closely with partner companies to employ their suite of rationally-derived stabilisation technologies.